Company intelligence / Profile preview

XI

San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Xi is a pre-clinical stage biotechnology company focused on developing next-generation therapeutics for oncology and autoimmune diseases. The company utilizes its proprietary Xi Discovery Platform to identify and optimize novel small molecule and protein-based drug candidates. By leveraging advanced computational biology and high-throughput screening, Xi aims to address high unmet medical needs in complex disease areas. The company is currently advancing several internal programs toward IND-enabling studies while exploring strategic partnerships for its platform technology.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProtein
Industry: Biotech

Beyond the preview

Go deeper on XI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XI.

Explore the full profile